CardioEffect - Cor.4U impedance analysis service

Cells Cor.4U® human iPS-derived cardiomyocytes
Species Human iPS cells of 26y/o Caucasian female
Service Type functional / phenotypic analysis
Delivery A study protocol will be sent to initiate the study. Results are sent as draft and final study report.
Timelines Experiment run time: 1 week per plate
Draft report: within 4 weeks
  This email address is being protected from spambots. You need JavaScript enabled to view it. 

 


 

ADVANTAGES 

  • Predictive, relevant and robust 96-well assay system based on integrated cell culture model representing primary-like cardiac physiology
  • Analysis of both acute and long-term effects on cardiomyocyte beating and overall cell health; combination with other read-outs of cell viability and cytotoxicity possible
  • Time- and cost effective assessment of compound safety accelerating lead selection

 

Axiogenesis CardioEffect compond reactions

Exemplary depiction of compound effects

 

Technology overview

CardioEffect combines Cor.4U® human cardiomyocytes with impedance technology (xCELLigence RTCA Cardio, ACEA Biosystems) to provide a homogenous and standardized assay system for in vitro detection of compound effects on cell beating. This includes changes of spike amplitude, beating frequency, induction of arrhythmia, and beating arrest.

 

 

Axiogenesis CardioEffect Time and concentration dependent doxorubicine effectAssessment of compound effects on human cardiomyocyte parameters using xCELLigence impedance technology.  The picture shows representative impedance traces after compound application. Pro-arrhythmic activity is detectable as early as 30 min after compound application. Beating cessation occurs after 24 h of exposure.

 

CardioEffect has been validated in house using 24 drugs with known cardiac safety profiles. Through years of service, Axiogenesis has experience with hundreds of compounds from a variety of classes and indications. Reference compounds are included on each assay plate for quality assurance. In addition to phenotypic assessment of contractile motion, this assay provides a surrogate measure of cytotoxicity via the “Cell Index”.

  

Axiogenesis CardioEffect graphical analysis of cell attachement and spreading via cell indexGraphical analysis of cell attachment and spreading monitored via Cell Index (CI). Doxorubicin decreases CI at clinically relevant concentrations.

 

 

CardioEffect provides an ideal tool to assess cardiomyocyte function, safety pharmacology / toxicity effects of drug candidates, etc. on human cardiac myocytes in a label-free, real time assay. Understanding cardiotoxic liabilities of compounds in early stages of drug development establishes confidence to move lead compounds towards pre-clinical and clinical development.

 

The CardioEffect Screening has been validated in house using 24 drugs with known cardiac safety profile. Reference compounds are included on each assay plate to ensure reproducible results.

Axiogenesis CardioEffect plate layout exampleTypical plate layout in 96-well format. Each plate includes reference compounds E-4031 and isoproterenol. TA = test article

 

Advantages of CardioEffect Screening Service

  • Integrated cell culture model representing primary-like cardiac physiology.
  • Predictive, relevant and robust assay system.
  • Assessement of both acute and long-term effects on cardiomyocyte function (beating) and overall health
  • Combination with other read-outs of cell viability and cytotoxicity possible.
  • Early and quick results on a compound's safety profile, time- and cost effective.

FIND US

Nattermannallee 1, Bldg S20
50829 Cologne
Germany –  (Map)

600 W Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
USA – (Map)

EMAIL US

Orders: order@axiogenesis.com
Support: support@axiogenesis.com
Other: office@axiogenesis.com

FOLLOW US

Twitter:  |   LinkedIn:  |   Newsletter:  Subscribe Axiogenesis Newsletter

CALL US

Phone (Main)
+49 221 99 88 18-0

Phone (US)
+1 844-511-6959

Fax + 49 221 99 88 18-10